Factor | Category | Cause-specific survival | Recurrence-free survival | ||||||
---|---|---|---|---|---|---|---|---|---|
Univariate | Multivariate | Univariate | Multivariate | ||||||
p value | p value | HRa | (95% CIb) | p value | p value | HR | (95% CIb) | ||
Age | < 70 (vs. ≥70) | 0.853 | 0.129 | ||||||
Sex | Male (vs. Female) | 0.796 | 0.398 | ||||||
Body mass index | < 20 (vs. ≥20) | 0.378 | 0.328 | ||||||
Tumor location | Utc (vs. Mtd or Lte) | 0.868 | 0.791 | ||||||
Histology | non-SCCf (vs. SCC) | 0.113 | 0.017* | 0.088 | 1.760 | (0.919–3.369) | |||
Neoadjuvant chemotherapy | Present (vs. Absent) | 0.689 | 0.138 | ||||||
Adjuvant chemotherapy | Present (vs. Absent) | 0.007* | 0.325 | 1.731 | (0.581–5.155) | 0.120 | |||
cT factor | cT2–3 (vs. T1) | 0.054 | 0.871 | 0.926 | (0.366–2.343) | 0.004* | 0.205 | 1.558 | (0.784–3.094) |
Clinical mediastinal lymph node metastasis | Present (vs. Absent) | 0.023* | 0.811 | 0.908 | (0.413–1.998) | 0.005* | 0.699 | 1.131 | (0.607–2.108) |
Clinical abdominal lymph node metastasis | Present (vs. Absent) | 0.000* | 0.000* | 3.917 | (1.860–8.250) | 0.000* | 0.007* | 2.162 | (1.237–3.781) |
Thoracic approach | VATSg (vs. OTh) | 0.000* | 0.017* | 0.387 | (0.178–0.842) | 0.001* | 0.021* | 0.514 | (0.292–0.902) |
Abdominal approach | HALSi (vs. OLj) | 0.170 | 0.100 | ||||||
Reconstruction route | mediastinal or antethoracic (vs. Retrosternal) | 0.105 | 0.398 |